Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/mus.27024 http://scihub22266oqcxt.onion/10.1002/mus.27024 32678460!7405390!32678460     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Muscle+Nerve 2020 ; 62 (4): 485-491 Nephropedia Template TP {{tp|p=32678460|t=2020. COVID-19-associated Guillain-Barre syndrome: The early pandemic experience |pdf=|usr=}}{{32678460}} gab.com Text COVID-19-associated Guillain-Barre syndrome: The early pandemic experience JO: Muscle Nerve http://www.kidney.de/pget.php?&tw=1&pmid=32678460 #FOAvip Guillain-Barre syndrome (GBS) is an inflammatory polyradiculoneuropathy associated with numerous viral infections. Recently, there have been many case reports describing the association between coronavirus disease-2019 (COVID-19) and GBS, but much remains unknown about the strength of the association and the features of GBS in this setting. We reviewed 37 published cases of GBS associated with COVID-19 to summarize this information for clinicians and to determine whether a specific clinical or electrodiagnostic (EDx) pattern is emerging. The mean age (59 years), gender (65% male), and COVID-19 features appeared to reflect those of hospitalized COVID-19 patients early in the pandemic. The mean time from COVID-19 symptoms to GBS symptoms was 11 days. The clinical presentation and severity of these GBS cases was similar to those with non-COVID-19 GBS. The EDx pattern was considered demyelinating in approximately half of the cases. Cerebrospinal fluid, when assessed, demonstrated albuminocytologic dissociation in 76% of patients and was negative for severe acute respiratory distress syndrome-coronavirus-2 (SARS-CoV-2) in all cases. Serum antiganglioside antibodies were absent in 15 of 17 patients tested. Most patients were treated with a single course of intravenous immunoglobulin, and improvement was noted within 8 weeks in most cases. GBS-associated COVID-19 appears to be an uncommon condition with similar clinical and EDx patterns to GBS before the pandemic. Future studies should compare patients with COVID-19-associated GBS to those with contemporaneous non-COVID-19 GBS and determine whether the incidence of GBS is elevated in those with COVID-19. Twit Text FOAVip COVID-19-associated Guillain-Barre syndrome: The early pandemic experience ????Muscle Nerve http://www.kidney.de/pget.php?&tw=1&pmid=32678460 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32678460 #FOAvip English Wikipedia <ref>{{Cite pmid|32678460}}</ref> COVID-19-associated Guillain-Barre syndrome: The early pandemic experience #MMPMID32678460 Caress JB; Castoro RJ; Simmons Z; Scelsa SN; Lewis RA; Ahlawat A; Narayanaswami P Muscle Nerve 2020[Oct]; 62 (4): 485-491 PMID32678460show ga Guillain-Barre syndrome (GBS) is an inflammatory polyradiculoneuropathy associated with numerous viral infections. Recently, there have been many case reports describing the association between coronavirus disease-2019 (COVID-19) and GBS, but much remains unknown about the strength of the association and the features of GBS in this setting. We reviewed 37 published cases of GBS associated with COVID-19 to summarize this information for clinicians and to determine whether a specific clinical or electrodiagnostic (EDx) pattern is emerging. The mean age (59 years), gender (65% male), and COVID-19 features appeared to reflect those of hospitalized COVID-19 patients early in the pandemic. The mean time from COVID-19 symptoms to GBS symptoms was 11 days. The clinical presentation and severity of these GBS cases was similar to those with non-COVID-19 GBS. The EDx pattern was considered demyelinating in approximately half of the cases. Cerebrospinal fluid, when assessed, demonstrated albuminocytologic dissociation in 76% of patients and was negative for severe acute respiratory distress syndrome-coronavirus-2 (SARS-CoV-2) in all cases. Serum antiganglioside antibodies were absent in 15 of 17 patients tested. Most patients were treated with a single course of intravenous immunoglobulin, and improvement was noted within 8 weeks in most cases. GBS-associated COVID-19 appears to be an uncommon condition with similar clinical and EDx patterns to GBS before the pandemic. Future studies should compare patients with COVID-19-associated GBS to those with contemporaneous non-COVID-19 GBS and determine whether the incidence of GBS is elevated in those with COVID-19. |*Betacoronavirus[MESH] |*Pandemics[MESH] |Brain/*diagnostic imaging[MESH] |COVID-19[MESH] |Coronavirus Infections/*complications/epidemiology[MESH] |Guillain-Barre Syndrome/diagnosis/*etiology/physiopathology[MESH] |Humans[MESH] |Magnetic Resonance Imaging[MESH] |Neural Conduction/*physiology[MESH] |Pneumonia, Viral/*complications/epidemiology[MESH] |SARS-CoV-2[MESH]COVID-19-associated Guillain-Barre syndrome: The early pandemic experi(epmc).pdf DeepDyve Pubget Overpricing